Update: Allersys launch targeted for spring 2016
H1 results (30 November 2015) noted that the Allersys allergy system could launch in spring 2016, with 37 optimised assays out of 40 targeted for launch. Omega’s Visitect CD4 test to monitor HIV patients shows a variability related to the ambient temperature. The cause is now known and a solution is being developed; the launch date is still uncertain. An Indian production facility in Pune starts operation in FY17 and should lead to sales gains in infectious disease products. Overall H1 sales were up 8% at £6.2m. Adjusted EPS was higher at 0.6p vs 0.5p due to a £135k tax credit.Omega Diagnostics Group is a holding company. Through its subsidiaries, Co. is engaged in the manufacturing, development and distribution of medical diagnostics products. Co. has three operating divisions: Allergy and autoimmune, which in the research, development, production and marketing of in-vitro allergy and autoimmune tests; Food intolerance, which provides clinical analysis to the general public, clinics and health professionals as well as supplying the consumer; and Infectious disease and Other, which comprise of research, development, production and marketing of kits to aid the diagnosis of infectious diseases.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.